Nanoplatform-Mediated Autophagy Regulation and Combined Anti-Tumor Therapy for Resistant Tumors

Area of Science:

• Oncology
• Nanomedicine
• Pharmacology

Background:

• Global cancer incidence and mortality are rising, with conventional therapies facing limitations like multidrug resistance (MDR) and systemic toxicity.
• Autophagy plays a critical role in tumor resistance to cancer therapies.
• There is a pressing need for innovative treatments that enhance efficacy, reduce adverse effects, and overcome drug resistance.

Purpose of the Study:

• To explore the potential of combining autophagy regulators with anti-tumor drugs using nanoplatforms for improved cancer treatment.
• To investigate nanotechnology-based strategies for overcoming limitations of current combination therapies, particularly in drug-resistant tumors.
• To highlight the prospects of nanomaterials with autophagy regulatory properties in cancer adjuvant therapy.

Main Methods:

• Review and synthesis of current research on combination therapy involving autophagy regulators and anti-tumor drugs.
• Exploration of nanotechnology-based co-delivery systems for enhanced therapeutic outcomes.
• Discussion of the role of nanomaterials with intrinsic autophagy regulatory properties.

Main Results:

• Combination therapy with autophagy regulators shows promise in overcoming tumor resistance and sensitizing anti-tumor drugs.
• Nanotechnology-based co-delivery systems offer a viable strategy to improve efficacy and reduce toxicity of combined treatments.
• Autophagy-regulating nanomaterials present potential as carriers, especially in adjuvant cancer therapy.

Conclusions:

• Nanotechnology-based co-delivery of autophagy regulators and anti-tumor drugs is a promising strategy for treating drug-resistant cancers.
• Further research is essential to address challenges in nanomedicine, including safety, biocompatibility, and side effects.
• Clinical studies are crucial to validate the application of these nanomedicine approaches in human cancer treatment.